Lei Huang

Lei Huang is currently the Associate Director of CMC Drug Substance mAb-ADC at BioNTech SE. From 2020 to 2021, they held various engineering roles at WuXi Biologics, contributing to downstream process development, tech transfer, and GMP production of the Covid-19 vaccine. Between 2018 and 2020, Huang worked as a researcher at Aarhus University, managing a German Research Foundation project and supervising graduate students. They are pursuing a Doctor of Philosophy (PhD) in Biocatalysis at Hamburg University of Technology, alongside a Bachelor of Engineering in Biotechnology from Northwest University and a Master of Engineering in Protein Engineering from East China University of Science and Technology.